How Liquid Biopsy Holds Promise for Early Detection of Breast Cancer with Marty Keiser & Liz Cormier-May, Mammogen, Inc.
8 October 2021
"Woman-led Mammogen Inc. is looking for breast cancers in a whole new way: using liquid biopsy to detect cancers far earlier, for more women, and with greater accuracy than traditional mammograms. They're also passionate about building a community to support women well beyond their initial diagnosis. A special look at the promising future for earlier breast cancer detection, in recognition of Breast Cancer Awareness Month!"
NEWPORT BEACH, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Mammogen, a female-led predictive health company developing RNA-powered molecular diagnostics for women’s health, today appointed Elise Berman, M.D., as Chief Medical Officer. Dr. Berman brings more than two decades of leadership across breast imaging, medical affairs, and clinical development. She joins Mammogen as the company advances genTRU-breast™ through clinical validation and toward commercialization.
Mammogen has announced the successful completion of a Series A financing round of up to $30 million, marking a significant milestone in the company's mission to transform breast cancer detection through innovative blood-based diagnostics.
Renowned global builder of boards and executive teams aligns with leading women's health innovator, signaling next phase of commercial growth